Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer
Abstract Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusio...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1998 |
|---|
| Umfang: |
4 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Investigational new drugs - 1983, 16(1998) vom: März, Seite 255-258 |
| Übergeordnetes Werk: |
volume:16 ; year:1998 ; month:03 ; pages:255-258 ; extent:4 |
| Links: |
|---|
| Katalog-ID: |
NLEJ197071848 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ197071848 | ||
| 003 | DE-627 | ||
| 005 | 20230506162356.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070527s1998 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ197071848 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer |
| 264 | 1 | |c 1998 | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered. Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Rajagopalan, Kumar |4 oth | |
| 700 | 1 | |a Peereboom, David |4 oth | |
| 700 | 1 | |a Budd, G. Thomas |4 oth | |
| 700 | 1 | |a Olencki, Thomas |4 oth | |
| 700 | 1 | |a Murthy, Siva |4 oth | |
| 700 | 1 | |a Elson, Paul |4 oth | |
| 700 | 1 | |a McLain, Denise |4 oth | |
| 700 | 1 | |a Bukowski, Ronald |4 oth | |
| 773 | 0 | 8 | |i in |t Investigational new drugs |d 1983 |g 16(1998) vom: März, Seite 255-258 |w (DE-627)NLEJ188985484 |w (DE-600)2009846-7 |x 1573-0646 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:1998 |g month:03 |g pages:255-258 |g extent:4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1023/A:1006195815320 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 1998 |c 3 |h 255-258 |g 4 | ||
| matchkey_str |
article:15730646:1998----::hsitilficdaifsofouiieurnomnrfatrm |
|---|---|
| hierarchy_sort_str |
1998 |
| publishDate |
1998 |
| allfields |
(DE-627)NLEJ197071848 DE-627 ger DE-627 rakwb eng Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer 1998 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered. Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer. Springer Online Journal Archives 1860-2002 Rajagopalan, Kumar oth Peereboom, David oth Budd, G. Thomas oth Olencki, Thomas oth Murthy, Siva oth Elson, Paul oth McLain, Denise oth Bukowski, Ronald oth in Investigational new drugs 1983 16(1998) vom: März, Seite 255-258 (DE-627)NLEJ188985484 (DE-600)2009846-7 1573-0646 nnns volume:16 year:1998 month:03 pages:255-258 extent:4 http://dx.doi.org/10.1023/A:1006195815320 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 16 1998 3 255-258 4 |
| spelling |
(DE-627)NLEJ197071848 DE-627 ger DE-627 rakwb eng Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer 1998 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered. Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer. Springer Online Journal Archives 1860-2002 Rajagopalan, Kumar oth Peereboom, David oth Budd, G. Thomas oth Olencki, Thomas oth Murthy, Siva oth Elson, Paul oth McLain, Denise oth Bukowski, Ronald oth in Investigational new drugs 1983 16(1998) vom: März, Seite 255-258 (DE-627)NLEJ188985484 (DE-600)2009846-7 1573-0646 nnns volume:16 year:1998 month:03 pages:255-258 extent:4 http://dx.doi.org/10.1023/A:1006195815320 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 16 1998 3 255-258 4 |
| allfields_unstemmed |
(DE-627)NLEJ197071848 DE-627 ger DE-627 rakwb eng Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer 1998 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered. Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer. Springer Online Journal Archives 1860-2002 Rajagopalan, Kumar oth Peereboom, David oth Budd, G. Thomas oth Olencki, Thomas oth Murthy, Siva oth Elson, Paul oth McLain, Denise oth Bukowski, Ronald oth in Investigational new drugs 1983 16(1998) vom: März, Seite 255-258 (DE-627)NLEJ188985484 (DE-600)2009846-7 1573-0646 nnns volume:16 year:1998 month:03 pages:255-258 extent:4 http://dx.doi.org/10.1023/A:1006195815320 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 16 1998 3 255-258 4 |
| allfieldsGer |
(DE-627)NLEJ197071848 DE-627 ger DE-627 rakwb eng Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer 1998 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered. Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer. Springer Online Journal Archives 1860-2002 Rajagopalan, Kumar oth Peereboom, David oth Budd, G. Thomas oth Olencki, Thomas oth Murthy, Siva oth Elson, Paul oth McLain, Denise oth Bukowski, Ronald oth in Investigational new drugs 1983 16(1998) vom: März, Seite 255-258 (DE-627)NLEJ188985484 (DE-600)2009846-7 1573-0646 nnns volume:16 year:1998 month:03 pages:255-258 extent:4 http://dx.doi.org/10.1023/A:1006195815320 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 16 1998 3 255-258 4 |
| allfieldsSound |
(DE-627)NLEJ197071848 DE-627 ger DE-627 rakwb eng Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer 1998 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered. Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer. Springer Online Journal Archives 1860-2002 Rajagopalan, Kumar oth Peereboom, David oth Budd, G. Thomas oth Olencki, Thomas oth Murthy, Siva oth Elson, Paul oth McLain, Denise oth Bukowski, Ronald oth in Investigational new drugs 1983 16(1998) vom: März, Seite 255-258 (DE-627)NLEJ188985484 (DE-600)2009846-7 1573-0646 nnns volume:16 year:1998 month:03 pages:255-258 extent:4 http://dx.doi.org/10.1023/A:1006195815320 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 16 1998 3 255-258 4 |
| language |
English |
| source |
in Investigational new drugs 16(1998) vom: März, Seite 255-258 volume:16 year:1998 month:03 pages:255-258 extent:4 |
| sourceStr |
in Investigational new drugs 16(1998) vom: März, Seite 255-258 volume:16 year:1998 month:03 pages:255-258 extent:4 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Investigational new drugs |
| authorswithroles_txt_mv |
Rajagopalan, Kumar @@oth@@ Peereboom, David @@oth@@ Budd, G. Thomas @@oth@@ Olencki, Thomas @@oth@@ Murthy, Siva @@oth@@ Elson, Paul @@oth@@ McLain, Denise @@oth@@ Bukowski, Ronald @@oth@@ |
| publishDateDaySort_date |
1998-03-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188985484 |
| id |
NLEJ197071848 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ197071848</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506162356.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1998 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ197071848</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered. Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rajagopalan, Kumar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peereboom, David</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Budd, G. Thomas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olencki, Thomas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Murthy, Siva</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Elson, Paul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McLain, Denise</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bukowski, Ronald</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Investigational new drugs</subfield><subfield code="d">1983</subfield><subfield code="g">16(1998) vom: März, Seite 255-258</subfield><subfield code="w">(DE-627)NLEJ188985484</subfield><subfield code="w">(DE-600)2009846-7</subfield><subfield code="x">1573-0646</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:1998</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:255-258</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1023/A:1006195815320</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">1998</subfield><subfield code="c">3</subfield><subfield code="h">255-258</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188985484 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1573-0646 |
| topic_title |
Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k r kr d p dp g t b gt gtb t o to s m sm p e pe d m dm r b rb |
| hierarchy_parent_title |
Investigational new drugs |
| hierarchy_parent_id |
NLEJ188985484 |
| hierarchy_top_title |
Investigational new drugs |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188985484 (DE-600)2009846-7 |
| title |
Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer |
| spellingShingle |
Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer |
| ctrlnum |
(DE-627)NLEJ197071848 |
| title_full |
Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer |
| journal |
Investigational new drugs |
| journalStr |
Investigational new drugs |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1998 |
| contenttype_str_mv |
zzz |
| container_start_page |
255 |
| container_volume |
16 |
| physical |
4 |
| format_se |
Elektronische Aufsätze |
| title_sort |
phase ii trial of circadian infusion floxuridine (fudr) in hormone refractory metastatic prostate cancer |
| title_auth |
Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer |
| abstract |
Abstract Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered. Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer. |
| abstractGer |
Abstract Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered. Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer. |
| abstract_unstemmed |
Abstract Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered. Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer |
| url |
http://dx.doi.org/10.1023/A:1006195815320 |
| remote_bool |
true |
| author2 |
Rajagopalan, Kumar Peereboom, David Budd, G. Thomas Olencki, Thomas Murthy, Siva Elson, Paul McLain, Denise Bukowski, Ronald |
| author2Str |
Rajagopalan, Kumar Peereboom, David Budd, G. Thomas Olencki, Thomas Murthy, Siva Elson, Paul McLain, Denise Bukowski, Ronald |
| ppnlink |
NLEJ188985484 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| up_date |
2024-07-06T08:07:24.761Z |
| _version_ |
1803816266380607488 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ197071848</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506162356.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1998 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ197071848</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered. Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rajagopalan, Kumar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peereboom, David</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Budd, G. Thomas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olencki, Thomas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Murthy, Siva</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Elson, Paul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McLain, Denise</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bukowski, Ronald</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Investigational new drugs</subfield><subfield code="d">1983</subfield><subfield code="g">16(1998) vom: März, Seite 255-258</subfield><subfield code="w">(DE-627)NLEJ188985484</subfield><subfield code="w">(DE-600)2009846-7</subfield><subfield code="x">1573-0646</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:1998</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:255-258</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1023/A:1006195815320</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">1998</subfield><subfield code="c">3</subfield><subfield code="h">255-258</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| score |
7.400504 |